Od dysforii do depresji. rola dynorfin i receptorów opioidowych kappa w patofizjologii chorób związanych ze stresem

• Authors: Przemysław Cieślak

Title variants

EN

From dysphoria to depression. The role of dynorphins and kappa opioid receptors in the pathophysiology of stress related disorders

• Languages of publication: PL EN

Abstracts

PL

Stres jest złożonym zjawiskiem, które wywiera wpływ na zdrowie i funkcjonowanie jednostki. Dynorfiny i receptory opioidowe kappa stanowią część endogennego systemu, który kontroluje homeostazę organizmu. Pod wpływem działania stresorów, dynorfiny wydzielane są, w strukturach mózgu istotnych dla kontroli reakcji stresowej. Pobudzeniu receptorów opioidowych kappa towarzyszy analgezja i awersja, które motywują do ucieczki w sytuacji zagrożenia. Jednak na skutek chronicznego stresu, długotrwałe pobudzenie receptorów opioidowych kappa może powodować uwrażliwienie organizmu na działanie stresorów i tym samym przyczyniać się do rozwoju chorób związanych ze stresem. Dane przedkliniczne wskazują, że antagoniści tego receptora mogą przynieść korzyści w leczeniu depresji, zaburzeń lękowych i uzależnień.

EN

Stress is a complex phenomenon which influences organism's health and functioning. Dynorphins and kappa opioid receptors are part of endogenous system which controls organism's homeostasis. Stressors induce dynorphins secretion in brain structures involved in control of stress reaction. Kappa opioid receptor-mediated analgesia and aversion motivates to escape threat. However, chronic stress and prolonged kappa opioid receptor activation can induce stress sensitization, and cause increase in risk of stress related disorders. Preclinical data suggests that kappa opioid receptor by antagonists have potential for treatment of depression, anxiety disorders and addiction.

• Journal: Kosmos
• Year: 2013
• Volume: 62
• Issue: 4
• Pages: 485-490

Dates

published

2013

Contributors

author

Przemysław Cieślak

• Instytut Farmakologii PAN, Smętna 12, 31-343, Kraków, Polska

References

• Bals-Kubik R., Ableitner A., Herz A., Shippenberg T. S., 1993. Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats. J. Pharmacol. Exp. Ther. 264, 489-495.
• Bilkei-Gorzo A., Racz I., Michel K., Mauer D., Zimmer A., Klingmüller D., Zimmer A., 2008. Control of hormonal stress reactivity by the endogenous opioid system. Psychoneuroendocrinology 33, 425-436.
• Bilkei-Gorzo A., Erk S., Schürmann B., Mauer D., Michel K., Boecker H., Scheef L., Walter H., Zimmer A., 2012. Dynorphins regulate fear memory: from mice to man. J. Neurosci. 32, 9335-9343.
• Bruchas M. R., Chavkin C., 2010. Kinase cascades and ligand-directed signaling at the kappa opioid receptor. Psychopharmacology 210, 137-147.
• Bruchas M. R., Land B. B., Aita M., Xu M., Barot S. K., Li S., Chavkin C., 2007. Stress-induced p38 mitogen-activated protein kinase activation mediates kappa-opioid-dependent dysphoria. J. Neurosci. 27, 11614-11623.
• Bruchas M. R., Land B. B., Lemos J. C., Chavkin C., 2009. CRF1-R activation of the dynorphin/kappa opioid system in the mouse basolateral amygdala mediates anxiety-like behavior. PLoS ONE 4, e8528.
• Bruchas M. R., Land B. B., Chavkin C., 2010. The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors. Brain Res. 1314, 44-55.
• Bruchas M. R., Schindler A. G., Shankar H., Messinger D. I., Miyatake M., Land B. B., Lemos J. C., Hagan C., Neumaier J. F., Quintana A., Palmiter R. D., Chavkin C., 2011. Selective p38α MAPK deletion in serotonergic neurons produces stress resilience in models of depression and addiction. Neuron 71, 498-511.
• Bruijnzeel A. W., 2009. Kappa-opioid receptor signaling and brain reward function. Brain Res. Rev. 62, 127-146.
• Carlezon W. A. Jr., Beguin C., Knoll A. T., Cohen B. M., 2009. Kappa-opioid ligands in the study and treatment of mood disorders. Pharmacol. Ther. 123, 334-343.
• Chavkin C., Jasmes I. F., Goldstein A., 1982. Dynorphin is a specific endogenous ligand of the kappa opioid receptor. Science 215, 413-415.
• de Kloet R. E., Joëls M., Holsboer F., 2005. Stress and the brain: from adaptation to disease. Nat. Rev. Neurosci. 6, 463-475.
• Ebner S. R., Roitman M. F., Potter D. N., Rachlin A. B., Chartoff E. H., 2010. Depressive-like effects of the kappa opioid receptor agonist salvinorin A are associated with decreased phasic dopamine release in the nucleus accumbens. Psychopharmacology 210, 241-252.
• Hashimoto K., Shimizu E., Iyo M., 2004. Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res. Rev. 45, 104-114.
• Knoll A. T., Carlezon W. A. Jr., 2010. Dynorphin, stress, and depression. Brain Res. 1314, 56-73.
• Knoll A. T., Meloni E. G., Thomas J. B., Carroll F. I., Carlezon W. A. Jr., 2007. Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats. J. Pharmacol. Exp. Ther. 323, 838-845.
• Koob G., Kreek M. J., 2007. Stress, dysregulation of drug reward pathways, and the transition to drug dependence. Am. J. Psychiatry 164, 1149-1159
• Kreibich A., Reyes B. A., Curtis A. L., Ecke L., Chavkin, C., Van Bockstaele E. J., Valentino R. J., 2008. Presynaptic inhibition of diverse afferents to the locus ceruleus by kappa-opiate receptors: a novel mechanism for regulating the central norepinephrine system. J. Neurosci. 28, 6516-6525.
• Land B. B., Bruchas M. R., Lemos J. C., Xu M., Melief E. J., Chavkin C., 2008. The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system. J. Neurosci. 28, 407-414.
• Land B. B., Bruchas M. R., Schattauer S., Giardino W. J., Aita M., Messinger D., Hnasko T. S., Palmiter R. D., Chavkin C., 2009. Activation of the kappa opioid receptor in the dorsal raphe nucleus mediates the aversive effects of stress and reinstates drug seeking. Proc. Natl. Acad. Sci. USA 106, 19168-19173.
• Lemos J. C., Chavkin C., 2011. Kappa opioid receptor function. [W:] The opiate receptors. The Receptors 23. Pasternak G. W. (red.). Humana Press, 265-305.
• López-Muñoz F., Alamo C., 2009. Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Curr. Pharm. Des. 15, 1563-1586.
• Margolis E. B., Hjelmstad G. O., Bonci A., Fields H. L., 2003. Kappa-opioid agonists directly inhibit midbrain dopaminergic neurons. J. Neurosci. 23, 9981-9986.
• Margolis E. B., Lock H., Chefer V. I., Shippenberg T. S., Hjelmstad G. O., Fields H. L., 2006. Kappa opioids selectively control dopaminergic neurons projecting to the prefrontal cortex. Proc. Natl. Acad. Sci. USA 103, 2938-2942.
• McEwen B. S., Eiland L., Hunter R. G., Miller M. M., 2011. Stress and anxiety: Structural plasticity and epigenetic regulation as a consequence of stress. Neuropsychopharmacology 62, 3-12.
• McLaughlin J. P., Marton-Popovici M., Chavkin C., 2003. Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses. J. Neurosci. 23, 5674-5683.
• McLaughlin J. P., Land B. B., Li S., Pintar J. E., Chavkin C., 2006. Prior activation of kappa opioid receptors by U50,488 mimics repeated forced swim stress to potentiate cocaine place preference conditioning. Neuropsychopharmacology 31, 787-794.
• Nestler E. J., Carlezon W. A. Jr., 2006. The mesolimbic dopamine reward circuit in depression. Biol. Psychiatry 59, 1151-1159.
• Pfeiffer A., Brantl V., Herz A., Emrich H. M., 1986. Psychotomimesis mediated by kappa opiate receptors. Science 233, 774-776.
• Pittenger C., Duman R. S., 2008. Stress, depression, neuroplasticity: a gonvergence of mechanisms. Neuropsychopharmacology 33, 88-109.
• Przewłocki R., 2009. Stress, opioid peptides, and their receptors. [W:] Hormones, brain and behavior. Pfaff D. W., Arnold A. P., Fahrbach S. E., Etgen A. M., Rubin R. T. (red.). Academic Press, 289-332.
• Redila V. A., Chavkin C., 2008. Stress-induced reinstatement of cocaine seeking is mediated by the kappa opioid system. Psychopharmacology 200, 59-70.
• Sapolsky R.M., 2000. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch. Gen. Psychiatry 57, 925-935
• Schwarzer C., 2009. 30 years of dynorphins - new insights on their functions in neuropsychiatric diseases. Pharmacol. Ther. 123, 353-370.
• Shirayama Y., Ishida H., Iwata M., Hazama G. I., Kawahara R., Duman R. S., 2004. Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant-like effects. J. Neurochem. 90, 1258-1268.
• Sperling R. E., Gomes S. M., Sypek E. I., Carey A. N., McLaughlin J. P., 2010. Endogenous kappa-opioid mediation of stress-induced potentiation of ethanol-conditioned place preference and self-administration. Psychopharmacology 2010, 199-209.
• Todtenkopf M. S., Marcus J. F., Portoghese P. S., Carlezon W. A. Jr., 2004. Effects of kappa-opioid receptor ligands on intracranial self-stimulation in rats. Psychopharmacology 172, 463-470.
• Wee S., Koob G. F., 2010. The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse. Psychopharmacology 210, 121-135.
• Wise R. A., 2004. Dopamine, learning and motivation. Nat. Rev. Neurosci. 5, 483-494.
• Wittmann W., Schunk E., Rosskothen I., Gaburro S., Singewald N., Herzog H., Schwarzer, C., 2009. Prodynorphin-derived peptides are critical modulators of anxiety and regulate neurochemistry and corticosterone. Neuropsychopharmacology 34, 775-785.
• Zhang H., Shi Y. G., Woods J. H., Watson S. J., Ko M. C., 2007.Central kappa-opioid receptor-mediated antidepressant-like effects of nor-Binaltorphimine : behavioral and BDNF mRNA expression studies. Eur. J. Pharmacol. 570, 89-96.